Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $652267.0.

  • Editas Medicine's Treasury Shares fell 7432.48% to $652267.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $652267.0, marking a year-over-year decrease of 7432.48%. This contributed to the annual value of $2.3 million for FY2024, which is 1041.1% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Treasury Shares is $652267.0, which was down 7432.48% from $923539.0 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Treasury Shares registered a high of $2.7 million during Q1 2024, and its lowest value of $628732.0 during Q4 2021.
  • Over the past 5 years, Editas Medicine's median Treasury Shares value was $1.5 million (recorded in 2025), while the average stood at $1.6 million.
  • Per our database at Business Quant, Editas Medicine's Treasury Shares soared by 13842.75% in 2022 and then tumbled by 7432.48% in 2025.
  • Editas Medicine's Treasury Shares (Quarter) stood at $628732.0 in 2021, then surged by 138.43% to $1.5 million in 2022, then surged by 40.56% to $2.1 million in 2023, then grew by 10.41% to $2.3 million in 2024, then plummeted by 71.96% to $652267.0 in 2025.
  • Its Treasury Shares was $652267.0 in Q3 2025, compared to $923539.0 in Q2 2025 and $1.5 million in Q1 2025.